Effectiveness of allergic rhinitis treatments in real-life with a focus on MP-AzeFlu

Ludger Klimek, Pascal Demoly, David Price

Research output: Contribution to journalLiterature review

1 Citation (Scopus)

Abstract

For any allergic rhinitis (AR) treatment, it is crucial to provide evidence not only of efficacy (assessed in randomized controlled trials (RCTs)) but also of effectiveness in real-life. Observational studies provide valuable data on the use and results associated with interventions prescribed in real-life. However, real-life evidence supporting available AR treatment options is sparse with effectiveness only established for oral antihistamines (desloratadine, ebastine), intranasal corticosteroids (mometasone furoate, fluticasone propionate (FP)), allergen immunotherapy and Omalizumab. A novel intranasal formulation of azelastine and FP in a single spray (MP-AzeFlu) shows great promise, with the effectiveness observed in real-life exceeding that noted in RCTs. This review summarises real-life data on MP-AzeFlu, which provides rapid and sustained symptom control irrespective of patient age, AR phenotype or disease severity. We call for high quality real-life research in addition to RCTs to inform future AR treatment guidelines.

Original languageEnglish
Pages (from-to)705-714
Number of pages10
JournalExpert Review of Clinical Pharmacology
Volume9
Issue number5
Early online date27 Feb 2016
DOIs
Publication statusPublished - 2016

Fingerprint

Mometasone Furoate
Randomized Controlled Trials
azelastine
Immunologic Desensitization
Therapeutics
Histamine Antagonists
Observational Studies
Adrenal Cortex Hormones
Quality of Life
Allergic Rhinitis
Guidelines
Phenotype
Research
Fluticasone
ebastine
desloratadine
Omalizumab

Keywords

  • allergic rhinitis
  • effectiveness
  • MP-AzeFlu
  • real-life

Cite this

Effectiveness of allergic rhinitis treatments in real-life with a focus on MP-AzeFlu. / Klimek, Ludger; Demoly, Pascal; Price, David.

In: Expert Review of Clinical Pharmacology, Vol. 9, No. 5, 2016, p. 705-714.

Research output: Contribution to journalLiterature review

@article{b0a11860017348efb3cb66e46443629a,
title = "Effectiveness of allergic rhinitis treatments in real-life with a focus on MP-AzeFlu",
abstract = "For any allergic rhinitis (AR) treatment, it is crucial to provide evidence not only of efficacy (assessed in randomized controlled trials (RCTs)) but also of effectiveness in real-life. Observational studies provide valuable data on the use and results associated with interventions prescribed in real-life. However, real-life evidence supporting available AR treatment options is sparse with effectiveness only established for oral antihistamines (desloratadine, ebastine), intranasal corticosteroids (mometasone furoate, fluticasone propionate (FP)), allergen immunotherapy and Omalizumab. A novel intranasal formulation of azelastine and FP in a single spray (MP-AzeFlu) shows great promise, with the effectiveness observed in real-life exceeding that noted in RCTs. This review summarises real-life data on MP-AzeFlu, which provides rapid and sustained symptom control irrespective of patient age, AR phenotype or disease severity. We call for high quality real-life research in addition to RCTs to inform future AR treatment guidelines.",
keywords = "allergic rhinitis, effectiveness, MP-AzeFlu, real-life",
author = "Ludger Klimek and Pascal Demoly and David Price",
year = "2016",
doi = "10.1586/17512433.2016.1148598",
language = "English",
volume = "9",
pages = "705--714",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Effectiveness of allergic rhinitis treatments in real-life with a focus on MP-AzeFlu

AU - Klimek, Ludger

AU - Demoly, Pascal

AU - Price, David

PY - 2016

Y1 - 2016

N2 - For any allergic rhinitis (AR) treatment, it is crucial to provide evidence not only of efficacy (assessed in randomized controlled trials (RCTs)) but also of effectiveness in real-life. Observational studies provide valuable data on the use and results associated with interventions prescribed in real-life. However, real-life evidence supporting available AR treatment options is sparse with effectiveness only established for oral antihistamines (desloratadine, ebastine), intranasal corticosteroids (mometasone furoate, fluticasone propionate (FP)), allergen immunotherapy and Omalizumab. A novel intranasal formulation of azelastine and FP in a single spray (MP-AzeFlu) shows great promise, with the effectiveness observed in real-life exceeding that noted in RCTs. This review summarises real-life data on MP-AzeFlu, which provides rapid and sustained symptom control irrespective of patient age, AR phenotype or disease severity. We call for high quality real-life research in addition to RCTs to inform future AR treatment guidelines.

AB - For any allergic rhinitis (AR) treatment, it is crucial to provide evidence not only of efficacy (assessed in randomized controlled trials (RCTs)) but also of effectiveness in real-life. Observational studies provide valuable data on the use and results associated with interventions prescribed in real-life. However, real-life evidence supporting available AR treatment options is sparse with effectiveness only established for oral antihistamines (desloratadine, ebastine), intranasal corticosteroids (mometasone furoate, fluticasone propionate (FP)), allergen immunotherapy and Omalizumab. A novel intranasal formulation of azelastine and FP in a single spray (MP-AzeFlu) shows great promise, with the effectiveness observed in real-life exceeding that noted in RCTs. This review summarises real-life data on MP-AzeFlu, which provides rapid and sustained symptom control irrespective of patient age, AR phenotype or disease severity. We call for high quality real-life research in addition to RCTs to inform future AR treatment guidelines.

KW - allergic rhinitis

KW - effectiveness

KW - MP-AzeFlu

KW - real-life

U2 - 10.1586/17512433.2016.1148598

DO - 10.1586/17512433.2016.1148598

M3 - Literature review

VL - 9

SP - 705

EP - 714

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 5

ER -